Home > Products > API > Degarelix
Degarelix
  • DegarelixDegarelix

Degarelix

Product nomen: Degarelix
Formulae hypotheticae: C82H103ClN18O16
Molecular pondus; 1632,26
CAS Subcriptio Number; 214766-78-6

Model:CAS NO:214766-78-6

Mitte Inquisitionem

depictio producti

Degarelix

Product nomen:Degarelix 214766-78-6
CAS No:214766-78-6
Specification: in domo

Nomen Degarelix
Synonyma DEGARELIX;Degarelixacetate;N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-4-[2,6 -dioxohexahydropyrimidin-4(S) -ylcarbo xamido]-L-phenylalanyl-4-ureido-D-phenylalanyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamideacetate; albook(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-(((4S)-2; 6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenyla lanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-;Degarelixacetate(FE-200486,Degarelix);FirMagon;
copyRight
M CAS # 59-02-9, Vitamin E, D-alpha-Tocopherol, (2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
Formulae hypotheticae C82H103ClN18O16
M. Pondus 1632.26
CAS Subcriptio Number 214766-78-6


Pertractatio et repono
Cautiones pro tutum pertractatio
Bene ventilatas tractantem in loco. Apta tutela vestitus. Pelle et oculis contactum fuge. Fuge formationem pulveris et aerosols. Utere instrumentis non-noctis. Ne ignis per electrostatic missionem vaporis.
Conditiones repono pro tuto, inter quaslibet incompatibilitates
Repone continens arcte clausum in loco sicco, frigido et bene ventilato. Disponunt a vasis victualibus vel materiae repugnantibus.

Imprimis usus finis (s): oeconomiae laboratoriae, ad investigationes scientificas et evolutionem tantum



Hot Tags: Degarelix, Sina, Suppliers, Manufacturers, Factory
Related Categoria
Mitte Inquisitionem
Libenter placet, ut inquisitionem tuam in forma infra exhibeas. Respondebimus tibi in 24 horis.
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept